César Matos Ribeiro da Silva

César Matos Ribeiro da Silva

Auto-generated profile, based on publicly available information

César Matos Ribeiro da Silva

Universidade Federal de Sergipe

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
CSCésar Matos Ribeiro da Silva
César Matos Ribeiro da Silva
WAWaleska da Silva Albuquerque
Waleska da Silva Albuquerque
JOJucyara Natállia Araujo de Oliveira
Jucyara Natállia Araujo de Oliveira
MCMaria Regina Pires Carneiro
Maria Regina Pires Carneiro
SJSona Jain
Sona Jain
ABAna Andréa Teixeira Barbosa
Ana Andréa Teixeira Barbosa
The objective of this study was to analyze the antimicrobial effect of nisin against MRSA (Methicillin-Resistant Staphylococcus aureus) and MSSA (Methicillin-Sensitive Staphylococcus aureus), and at the same time examine the possibility of the bacteria to develope nisin resistance. The antimicrobial susceptibility of the strains was tested using the agar diffusion and/or microdilution methods. To select nisin-resistant strains, bacteria were grown consecutively at sublethal concentrations of the bacteriocin. Nisin showed bactericidal activity against most of the tested strains. MRSA required higher doses of bacteriocin compared to MSSA both for inhibition and cell death. However, transfers in the presence of nisin could completely eliminate nisin activity with an increase in minimal inhibitory concentration value of up to 250 times. Nisin-resistance could be maintained in MRSA and MSSA even in the absence of the bacteriocin. Nisin resistance affected antibiotic susceptibility of both MRSA and MSSA to mainly Cefoxitin, Oxacillin, and Erythromycin. These results indicate that nisin-resistance is a complex trait among MSSA and MRSA and must be elucidated before the therapeutic recommendation of nisin to treat infections caused by these bacterial species.